Cargando…

Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis

OBJECTIVES: In year 2016, Danish national guidelines included a mandatory switch of patients with inflammatory rheumatic diseases treated with originator etanercept (ETA) to biosimilar SB4 in routine care. We aimed to explore if switching lead to increased healthcare utilisation and costs. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glintborg, Bente, Ibsen, Rikke, Bilbo, Rebecca Elisabeth Qwist, Lund Hetland, Merete, Kjellberg, Jakob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Treatments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691512/ https://www.ncbi.nlm.nih.gov/pubmed/31452931 http://dx.doi.org/10.1136/rmdopen-2019-001016

Ejemplares similares

Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis
por: Glintborg, Bente, et al.
Publicado: (2018)

Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis
por: Lindström, Ulf, et al.
Publicado: (2019)

Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?
por: Toussirot, Eric, et al.
Publicado: (2017)

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar
por: Felis-Giemza, Anna, et al.
Publicado: (2019)

Etanercept biosimilars
por: Azevedo, Valderilio F., et al.
Publicado: (2014)

The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO
por: Ibfelt, Else Helene, et al.
Publicado: (2016)

Morbidity and mortality in patients with rheumatoid arthritis compared with an age- and sex-matched control population: A nationwide register study
por: Løppenthin, Katrine, et al.
Publicado: (2019)

Biosimilars: what do patients need to consider?
por: Skingle, Diana
Publicado: (2015)

Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis
por: Ditto, Maria Chiara, et al.
Publicado: (2020)

Waiting for JAK inhibitor safety data
por: Kragstrup, Tue Wenzel, et al.
Publicado: (2022)

Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example
por: Lai, Zhihong, et al.
Publicado: (2016)

Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
por: Meijboom, Rosanne W., et al.
Publicado: (2021)

Mortality and use of psychotropic medication in patients with stroke: a population-wide, register-based study
por: Jennum, Poul, et al.
Publicado: (2016)

GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2017)

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
por: Ebbers, Hans C., et al.
Publicado: (2019)

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry
por: Nabi, Hafsah, et al.
Publicado: (2022)

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
por: Kiltz, Uta, et al.
Publicado: (2022)

Risk factors for Staphylococcus aureus bacteremia in patients with rheumatoid arthritis and incidence compared with the general population: protocol for a Danish nationwide observational cohort study
por: Dieperink, Sabine Sparre, et al.
Publicado: (2019)

Direct and indirect economic and health consequences of COPD in Denmark: a national register-based study: 1998–2010
por: Løkke, Anders, et al.
Publicado: (2014)

Focus on biosimilar etanercept – bioequivalence and interchangeability
por: Cantini, Fabrizio, et al.
Publicado: (2018)

Correction to: GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2018)

Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis
por: Gehin, Johanna Elin, et al.
Publicado: (2021)

Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database
por: Stajszczyk, Marcin, et al.
Publicado: (2023)

Reduced Humoral Response of SARS-CoV-2 Antibodies following Vaccination in Patients with Inflammatory Rheumatic Diseases—An Interim Report from a Danish Prospective Cohort Study
por: Schreiber, Karen, et al.
Publicado: (2021)

Long-term sickness absence of 32 chronic conditions: a Danish register-based longitudinal study with up to 17 years of follow-up
por: Nexo, Mette Andersen, et al.
Publicado: (2018)

Impact of red meat, processed meat and fibre intake on risk of late-onset chronic inflammatory diseases: prospective cohort study on lifestyle factors using the Danish ‘Diet, Cancer and Health’ cohort (PROCID-DCH): protocol
por: Rasmussen, Nathalie Fogh, et al.
Publicado: (2019)

Incidence of facial nerve palsies stratified by DMARD treatment in patients with rheumatoid arthritis: data from the RABBIT register
por: Meissner, Yvette, et al.
Publicado: (2020)

Intake of dietary fibre, red and processed meat and risk of late-onset Chronic Inflammatory Diseases: A prospective Danish study on the “diet, cancer and health” cohort
por: Rubin, Katrine Hass, et al.
Publicado: (2020)

Remission, response, retention and persistence to treatment with disease-modifying agents in patients with rheumatoid arthritis: a study of harmonised Swedish, Danish and Norwegian cohorts
por: Westerlind, Helga, et al.
Publicado: (2023)

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2023)

Early Treatment for Women with Alcohol Addiction (EWA) Reduces Mortality: A Randomized Controlled Trial with Long-Term Register Follow-up
por: Gjestad, Rolf, et al.
Publicado: (2011)

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
por: Chadwick, Laura, et al.
Publicado: (2018)

Physicochemical Characterization of Altebrel™, a Proposed Etanercept Biosimilar
por: Fazel, Ramin, et al.
Publicado: (2019)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
por: Moorkens, Evelien, et al.
Publicado: (2020)

Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study
por: Christensen, Ingrid Egeland, et al.
Publicado: (2022)

Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study
por: Fisher, Anat, et al.
Publicado: (2022)

Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease: protocol for an open cohort study
por: Kringelbach, Tina Marie, et al.
Publicado: (2018)

Morbidity in early Parkinson's disease and prior to diagnosis
por: Frandsen, Rune, et al.
Publicado: (2014)

All-cause mortality from obstructive sleep apnea in male and female patients with and without continuous positive airway pressure treatment: a registry study with 10 years of follow-up
por: Jennum, Poul, et al.
Publicado: (2015)

Risk of pre-eclampsia and impact of disease activity and antirheumatic treatment in women with rheumatoid arthritis, axial spondylarthritis and psoriatic arthritis: a collaborative matched cohort study from Sweden and Denmark
por: Secher, Anne Emilie Pape, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a0serbbgkoqhlnbgsg7fd264mn